United States Patent 8,088,407: Dexamethasone Ocular Implant Claims, Patent Scope and Competitive Landscape

US Patent No. 8,088,407 covers a treatment method for ocular edema using a bioerodible dexamethasone delivery system, with dependent claims directed to vitreous placement, PLGA polymers and minimum release periods. The patent is a method-of-treatment patent rather than a broad composition patent. Its practical relevance is tied to intravitreal dexamethasone implants, including the technology commercialized in Ozurdex.

The strongest claim combination is claim 1 combined with claims 2, 3 and 5: treatment of ocular edema by placing a dexamethasone-containing, PLGA-based bioerodible system in the vitreous that releases drug for at least about three weeks. The claims do not require a specific implant shape, dexamethasone dose, edema subtype, injection device or release profile beyond the stated duration.

What does US Patent 8,088,407 protect?

The patent protects the act of treating eye edema by placing a qualifying dexamethasone delivery system in the eye. The principal limitations are:

Limitation	Claim source	Scope
Treating edema in an eye	Claim 1	Requires an edema-treatment method, not merely delivery of dexamethasone
Placing a delivery system in the eye	Claim 1	Covers administration or implantation of the system
Dexamethasone	Claim 1	Requires dexamethasone as the therapeutic agent
Bioerodible polymer	Claim 1	Requires a polymeric system that erodes or degrades in vivo
Vitreous placement	Claim 2	Narrows claim 1 to placement in the vitreous
PLGA copolymer	Claim 3	Narrows the polymer to polylactic acid-polyglycolic acid
At least five days of delivery	Claim 4	Establishes a minimum release period
At least about three weeks of delivery	Claim 5	Establishes a more commercially relevant sustained-release limitation

Claim 1 is the broadest independent claim provided. It does not expressly require intravitreal administration, PLGA, a particular edema diagnosis or any defined release duration. Claims 2 through 5 narrow that scope.

How should claim 1 be construed?

Claim 1 has four central elements:

An individual has edema in an eye.
A bioerodible drug delivery system is placed in the eye.
The system contains dexamethasone and a bioerodible polymer.
The placement treats the edema.

A product does not necessarily infringe claim 1 merely because it contains dexamethasone and is bioerodible. The claim is directed to a method. Infringement would generally require performance of the claimed treatment method, including placement in an eye of an individual with edema.

The phrase "treating edema" is functional. It may encompass reducing fluid accumulation, improving retinal thickness, improving visual outcomes associated with edema or otherwise obtaining a therapeutic effect recognized for the treated ocular condition. The claim does not specify a numerical reduction in edema or a required visual-acuity endpoint.

The claim also does not expressly limit the edema to diabetic macular edema, retinal vein occlusion-associated macular edema, uveitic macular edema or postoperative edema. A product used for any qualifying ocular edema could fall within the literal wording if the other limitations are met.

What additional scope do claims 2 through 5 add?

Claim 2: vitreous placement

Claim 2 requires placing the delivery system in the vitreous. This is important because it narrows the method from any ocular placement to intravitreal administration.

The claim may cover an implant inserted through an intravitreal injection procedure, provided the implant is placed in the vitreous and the other claim 1 limitations are satisfied. It does not expressly require placement in the posterior segment, subretinal space, anterior chamber or vitreous cavity by a particular device.

A system placed only subconjunctivally, intracamerally or topically would not satisfy claim 2 without a broader interpretation of "in the vitreous."

Claim 3: PLGA polymer

Claim 3 specifies a polylactic acid-polyglycolic acid copolymer, commonly abbreviated PLGA. PLGA is widely used for biodegradable implants because its degradation rate can be adjusted through:

The lactic acid-to-glycolic acid ratio.
Polymer molecular weight.
End-group chemistry.
Implant dimensions.
Drug loading.
Porosity and fabrication method.

The claim does not state a required PLGA ratio, molecular weight, grade, implant geometry or manufacturing process. A competitor using a different bioerodible polymer could avoid claim 3 while potentially remaining within claim 1.

Claims 4 and 5: release duration

Claim 4 requires delivery of the immunosuppressive agent for at least five days. Claim 5 requires delivery for at least about three weeks. Dexamethasone is the agent identified in claim 1, while the dependent claims use the broader term "immunosuppressive agent."

Claim 5 is commercially significant because it targets sustained-release ocular implants rather than short-duration injections or conventional topical dosing. A system that releases dexamethasone for approximately three weeks or longer may satisfy the duration limitation, depending on how release is measured and how the claim is construed.

The claims do not define whether "delivers" means:

Detectable drug release.
Pharmacologically active release.
Release into the vitreous.
Delivery above a specified concentration.
Continuous release without interruptions.

Those issues could become central in claim construction or an infringement dispute.

Is US Patent 8,088,407 a composition patent or a method patent?

It is a method patent based on the claims provided.

The patent does not, in these claims, independently claim:

A dexamethasone implant as a composition.
A specific PLGA formulation.
A manufacturing process.
An applicator or injector.
A particular implant size.
A defined drug-to-polymer ratio.
A specific release-rate curve.

A competitor could therefore face different risks under separate composition, formulation, device or manufacturing patents even if it avoids the asserted method claim. Conversely, designing around the method claim may be possible through a non-bioerodible delivery system, a non-dexamethasone corticosteroid, a different administration site or a treatment indication outside the claim's construction.

What product technology is most closely associated with the patent?

The claim structure is closely aligned with biodegradable intravitreal dexamethasone implant technology, particularly the Ozurdex product marketed by AbbVie through its Allergan business.

Ozurdex is a biodegradable intravitreal implant containing dexamethasone in a PLGA-based matrix. The FDA-approved product is used for conditions including macular edema following branch retinal vein occlusion or central retinal vein occlusion, diabetic macular edema and noninfectious uveitis affecting the posterior segment of the eye.[2]

The product is inserted into the vitreous using a dedicated applicator. Its commercial design corresponds closely to the technical limitations in claims 2, 3 and 5:

Ozurdex-related characteristic	Relationship to claims
Intravitreal implant	Corresponds to claim 2
Dexamethasone active ingredient	Required by claim 1
Biodegradable polymer matrix	Required by claim 1
PLGA-based delivery system	Corresponds to claim 3
Sustained release over multiple weeks	Corresponds to claim 5
Treatment of retinal or posterior-segment edema	Corresponds to claim 1

The patent should not be analyzed in isolation. A commercial product can be protected by multiple patents covering the implant composition, drug loading, manufacturing process, applicator and methods of treating specific diseases.

What patents protect Ozurdex and related dexamethasone implants?

The relevant patent estate has included several patent families directed to biodegradable ocular implants and therapeutic use. US Patent 8,088,407 is best viewed as one component of that estate rather than the entire protection package.

Patent categories in the relevant estate

Patent category	Typical subject matter	Relevance to US 8,088,407
Method-of-treatment patents	Treating macular edema, uveitis or other ocular conditions	Directly relevant
Composition patents	Dexamethasone-polymer implant formulations	Complementary protection
Device patents	Applicators and delivery systems	Separate infringement analysis
Manufacturing patents	Compression, molding or implant fabrication	Manufacturing barrier
Release-profile patents	Sustained delivery over defined periods	May overlap technically
Indication patents	Use for diabetic macular edema or retinal vein occlusion	May narrow or extend practical protection

The distinction matters in generic litigation. A generic applicant may challenge the listed method patent while accepting that other formulation or device patents remain enforceable. A Paragraph IV certification against one patent does not automatically eliminate all patent barriers.

What is the Orange Book status of US Patent 8,088,407?

US Patent 8,088,407 has been associated with the patent protection for Ozurdex and related dexamethasone intravitreal implant products. Orange Book analysis should distinguish between:

Whether the patent is listed for the approved product.
Whether the patent's claims cover the approved indication.
Whether the patent remains unexpired.
Whether pediatric exclusivity extended the applicable regulatory period.
Whether later patents were added to the product's listing.

The FDA Orange Book identifies patents submitted by the New Drug Application holder for approved drug products.[1] A listing does not establish that every claim is valid or infringed. It affects the abbreviated new drug application process and the certification obligations of a generic applicant.

For a current regulatory determination, the controlling records are the FDA Orange Book product entry, the patent-use-code record and the USPTO Patent Center file. The patent's issue date alone does not determine its effective exclusivity period. Patent term depends on the earliest effective nonprovisional filing date, terminal disclaimers, patent-term adjustment and any applicable patent-term extension.

When did or does US Patent 8,088,407 lose exclusivity?

The patent's enforceability must be determined from the USPTO term record, not from the 2012 issue date. The relevant analysis includes:

The earliest effective US nonprovisional filing date.
Continuation and divisional relationships.
Any terminal disclaimer.
Patent-term adjustment.
Patent-term extension under 35 U.S.C. § 156.
Maintenance-fee status.
Any disclaimer or post-grant proceeding affecting the claims.

The patent is now outside the ordinary period in which an issued US patent from this family would normally provide a new long-term barrier unless a specific term adjustment or extension applies. A business relying on current exclusivity should use the official USPTO patent-term calculation and FDA listing rather than treating the issued patent as an independently enforceable asset.

The commercial importance of the patent therefore depends more on historical Orange Book litigation, accrued damages, related patents and settlement terms than on a standalone forward-looking monopoly.

What Paragraph IV challenges affect dexamethasone intravitreal implants?

A generic applicant seeking approval for an equivalent dexamethasone intravitreal implant may need to address listed patents through one or more certifications:

Certification	Meaning
Paragraph I	No patent information is listed
Paragraph II	Listed patent has expired
Paragraph III	Applicant will wait until patent expiry
Paragraph IV	Patent is invalid, unenforceable or will not be infringed
Section viii statement	Applicant will carve out a patented method of use

For an implant with the same active ingredient, route of administration and delivery characteristics, a Paragraph IV strategy could challenge composition, method or device patents. A section viii carve-out may be available for a patented indication if the remaining approved uses do not require the excluded method.

The claim set supplied here creates several possible attack points:

Whether the accused system is actually bioerodible.
Whether dexamethasone is delivered from the system.
Whether the system treats the claimed edema.
Whether the system is placed in the vitreous.
Whether PLGA is present.
Whether the release period reaches five days or approximately three weeks.
Whether the claims are enabled across the full range of ocular edema conditions.
Whether the claims are indefinite because release duration and treatment effect are not quantitatively defined.

What patent litigation and settlements are relevant?

Patent disputes involving ocular implants typically arise through ANDA litigation under the Hatch-Waxman Act. The litigation issues normally include:

Infringement of listed formulation patents.
Infringement of method-of-use patents.
Validity of broad biodegradable-implant claims.
Obviousness over prior sustained-release ocular systems.
Written description and enablement for broad ocular indications.
The effect of an indication carve-out.
Entry dates established by settlement.

A settlement may permit an authorized generic, a licensed generic, or a delayed launch before patent expiration. The existence of a settlement does not establish claim validity. The commercial impact depends on the agreed launch date, scope of the license, manufacturing rights and whether the agreement covers competing products.

No conclusion about a particular company's current Paragraph IV position or settlement date should be drawn from US Patent 8,088,407 alone. The relevant case docket, Orange Book certifications and settlement filings must be reviewed at the product level.

How strong is the patent estate?

Strengths

The claims have practical strength where a competing product uses the same core architecture:

Dexamethasone.
A bioerodible polymer.
Intravitreal placement.
PLGA.
Sustained delivery for several weeks.
Treatment of ocular edema.

The claims also avoid unnecessary restrictions on implant geometry, dose and polymer ratio. That breadth can make a design-around more difficult for a product intended to replicate the commercial implant.

Weaknesses

The claims have several potential vulnerabilities:

They are method claims and require performance of the treatment method.
Claim 1 does not expressly require intravitreal administration or PLGA.
The term "edema" is broad and may raise written-description or enablement questions.
"At least about three weeks" may create measurement and claim-construction disputes.
"Delivers" lacks a specified concentration or pharmacokinetic threshold.
The claims do not define the amount of dexamethasone.
The claims may be vulnerable to prior art involving biodegradable corticosteroid implants.
Patent expiration limits forward-looking value even if historical infringement exposure remains.

Overall, the patent is strongest against a product that copies the Ozurdex architecture and is marketed for the same edema indications. It is weaker as a standalone barrier against products using a different corticosteroid, non-bioerodible system, alternative delivery route or different therapeutic indication.

How does US 8,088,407 compare with competing ocular steroid patents?

Product or technology	Active agent	Delivery platform	Main patent risk relative to US 8,088,407
Ozurdex	Dexamethasone	Biodegradable intravitreal PLGA implant	Direct overlap
Retisert	Fluocinolone acetonide	Non-biodegradable intravitreal implant	Different active agent and platform
Iluvien	Fluocinolone acetonide	Injectable sustained-release implant	Different active agent; formulation patents apply
Yutiq	Fluocinolone acetonide	Injectable intravitreal implant	Different active agent and product estate
Conventional dexamethasone injection	Dexamethasone	Injectable solution or suspension	May avoid bioerodible-system limitations
Topical corticosteroid	Various	Topical ocular delivery	Generally outside the claimed implant method

The most direct competitive threat is another dexamethasone biodegradable intravitreal implant. Fluocinolone products compete clinically but are less likely to fall within the literal scope of the supplied claims because they use a different corticosteroid and, in some cases, a different implant platform.

What generic entry risks exist?

A generic or follow-on entrant faces four main risks.

First, an equivalent PLGA dexamethasone implant may implicate formulation and method claims at the same time. Second, the applicant may face an FDA patent certification dispute even if the method patent is near or past expiration, because later-listed patents can remain relevant. Third, an indication carve-out may reduce infringement exposure but also limit the commercial label. Fourth, the entrant may need a redesigned applicator or delivery system to avoid separate device patents.

Possible design-around strategies include:

Using a non-PLGA biodegradable polymer.
Using a non-bioerodible implant.
Using a different corticosteroid.
Changing the release period so it does not meet a disputed duration limitation.
Pursuing a different indication or label carve-out.
Using a delivery route other than vitreous placement.
Developing a formulation that releases drug rapidly rather than over several weeks.

Each design-around has regulatory and commercial consequences. A different polymer may require new biocompatibility, stability and release data. A different corticosteroid may require a separate clinical and regulatory program.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barriers are not limited to the claims provided. A commercially viable implant requires control of:

Polymer degradation.
Dexamethasone crystallinity and uniformity.
Implant mechanical strength.
Sterility and endotoxin levels.
Drug loading and content uniformity.
Release-rate reproducibility.
Applicator compatibility.
Shelf-life stability.
Injection force and implant placement.

These technical parameters may be covered by separate patents or trade secrets even where US 8,088,407 is no longer enforceable. Manufacturing know-how can therefore remain a practical barrier after formal patent expiry.

What is the commercial exposure associated with the patent?

The commercial exposure is concentrated in the intravitreal corticosteroid implant market. The key product markets include:

Diabetic macular edema.
Retinal vein occlusion-associated macular edema.
Noninfectious posterior uveitis.
Other retinal edema conditions treated off-label or under separate regulatory indications.

The revenue risk from a competing product depends on more than patent expiry. Important variables include:

FDA approval for the same indications.
Physician confidence in implant performance.
Injection-device usability.
Reimbursement and coding.
Duration of effect.
Need for repeat treatment.
Safety profile, including intraocular pressure and cataract risk.
Ability to secure pharmacy or physician-office distribution.
Availability of a generic or authorized generic.

A competitor that obtains approval for only a narrow indication may not immediately erode the entire branded market. Conversely, a fully substitutable implant with comparable duration and applicator performance could create substantial price pressure.

Key Takeaways

US Patent 8,088,407 is directed to treating ocular edema with a bioerodible dexamethasone delivery system.
Claim 1 is a broad method claim; claims 2 through 5 narrow it to vitreous placement, PLGA and sustained release.
The patent does not independently claim every dexamethasone implant composition, applicator or manufacturing process.
The closest commercial technology is the Ozurdex biodegradable intravitreal dexamethasone implant.
The patent is strongest against a direct copy using dexamethasone, PLGA, intravitreal placement and multiweek release.
Key validity and infringement issues include the meaning of "treating edema," "delivers," "at least about three weeks" and the scope of "bioerodible polymer."
Orange Book listing and current enforceability must be assessed separately from the patent's issue date.
A generic entrant may pursue Paragraph IV, a section viii indication carve-out or a formulation and delivery-system design-around.
Separate composition, device, manufacturing and indication patents may control market entry even after this patent's term has ended.

FAQs

Does US Patent 8,088,407 cover all dexamethasone eye treatments?

No. The supplied claims require a bioerodible drug delivery system containing dexamethasone and a bioerodible polymer. Conventional eye drops, non-bioerodible injections and other dexamethasone products may fall outside these claims.

Does a PLGA dexamethasone implant automatically infringe claim 3?

No. Claim 3 is a method claim. The relevant question is whether the implant is placed in an eye to treat edema under the conditions required by claim 1, with the PLGA limitation added by claim 3.

Can a competitor avoid the patent by using fluocinolone?

Potentially. Fluocinolone is not dexamethasone, so a fluocinolone implant would not satisfy the dexamethasone limitation as literally written. Separate patents covering fluocinolone products could still apply.

Does a three-week release period fall within claim 5?

It may. Claim 5 requires delivery for "at least about 3 weeks." The result depends on the claim construction of "about," the method used to measure release and whether the system delivers pharmacologically relevant drug during that period.

Does patent expiration eliminate all Ozurdex generic-entry barriers?

No. Expiration of one patent does not eliminate separate formulation, device, manufacturing or later-filed method patents. FDA approval requirements, patent listings and litigation settlements can continue to affect entry.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations (Orange Book). https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
U.S. Food and Drug Administration. (2023). Ozurdex (dexamethasone intravitreal implant) prescribing information.
U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
United States Patent No. 8,088,407. (2012). Methods for treating edema in an eye. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Orange Book patent and exclusivity information. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	306951	⤷ Start Trial
Australia	2002236495	⤷ Start Trial
Australia	2006201271	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,088,407

Summary for Patent: 8,088,407